In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TG Therapeutics Inc.

www.tgtherapeutics.com

Latest From TG Therapeutics Inc.

TG’s Follicular Lymphoma Data Suggest Umbralisib Could Succeed In PI3K Delta Class

Overall survival data from a follicular lymphoma cohort of its umbrella NHL study indicate umbralisib could match other PI3K delta inhibitors’ efficacy with better safety/tolerability profile.

Clinical Trials Business Strategies

Novartis's Ofatumumab Pursues Entrenched Competitors In MS

Novartis’s anti-CD20 MS candidate, ofatumumab, shows promise in initial findings from the ASCLEPIOS Phase III studies, but more details are needed to show how it stacks up against Sanofi’s Aubagio, and ultimately against Roche’s Ocrevus.

 

Clinical Trials Neurology

Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases

Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.

Financing Business Strategies

Keeping Track: Bad News For Bristol And Lilly, Good News For TG Therapeutics

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Atlantic Technology Ventures Inc.
  • Manhattan Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • TG Therapeutics Inc.
  • Senior Management
  • Michael S Weiss, Pres. & CEO
    Sean A Power, CFO
    Adam Waldman, Chief Commercial Officer
  • Contact Info
  • TG Therapeutics Inc.
    Phone: (212) 554-4484
    2 Gansevoort St.
    9th Floor
    New York , NY 10014
    USA
UsernamePublicRestriction

Register